Etiology and therapeutic management of erythema nodosum during pregnancy: An update

K. Alexandra Acosta, Mary Claire Haver, Brent Kelly

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Erythema nodosum (EN) is the most common form of panniculitis. It is characterized by erythematous, raised, tender nodules that usually occur bilaterally on the extensor surfaces of the lower extremities. EN is associated with many underlying conditions including infection, sarcoidosis, malignancy, and pregnancy. Its underlying etiology, however, is unknown in up to half of cases. Pregnancy is thought to create an optimal background for EN to develop, although the exact mechanisms are unclear. Immune complexes may play a role in the pathogenesis of EN during pregnancy, or EN may be a hypersensitivity reaction to either estrogens or progesterone. EN is a self-limiting process, and non-pharmacologic means such as bed rest and elastic web bandages may be sufficient to control the symptoms. Potassium iodide, systemic and intralesional corticosteroids, non-steroidal anti-inflammatory drugs, salicylates, tumor necrosis factor-α inhibitors, hydroxychloroquine, colchicine, and dapsone are other treatment options available, but some of these drugs are contraindicated in pregnancy while others are considered safe. Before prescribing one of these treatments to a pregnant patient, the patient's obstetrician should be consulted, and a careful risk-benefit analysis should be performed.

Original languageEnglish (US)
Pages (from-to)215-222
Number of pages8
JournalAmerican Journal of Clinical Dermatology
Volume14
Issue number3
DOIs
StatePublished - Jun 2013

Fingerprint

Erythema Nodosum
Pregnancy
Therapeutics
Compression Bandages
Panniculitis
Hydroxychloroquine
Potassium Iodide
Dapsone
Bed Rest
Salicylates
Colchicine
Sarcoidosis
Antigen-Antibody Complex
Pharmaceutical Preparations
Progesterone
Lower Extremity
Adrenal Cortex Hormones
Hypersensitivity
Estrogens
Anti-Inflammatory Agents

ASJC Scopus subject areas

  • Dermatology

Cite this

Etiology and therapeutic management of erythema nodosum during pregnancy : An update. / Acosta, K. Alexandra; Haver, Mary Claire; Kelly, Brent.

In: American Journal of Clinical Dermatology, Vol. 14, No. 3, 06.2013, p. 215-222.

Research output: Contribution to journalArticle

@article{82ab3c57c116472fbc37c41c9d2a5dc6,
title = "Etiology and therapeutic management of erythema nodosum during pregnancy: An update",
abstract = "Erythema nodosum (EN) is the most common form of panniculitis. It is characterized by erythematous, raised, tender nodules that usually occur bilaterally on the extensor surfaces of the lower extremities. EN is associated with many underlying conditions including infection, sarcoidosis, malignancy, and pregnancy. Its underlying etiology, however, is unknown in up to half of cases. Pregnancy is thought to create an optimal background for EN to develop, although the exact mechanisms are unclear. Immune complexes may play a role in the pathogenesis of EN during pregnancy, or EN may be a hypersensitivity reaction to either estrogens or progesterone. EN is a self-limiting process, and non-pharmacologic means such as bed rest and elastic web bandages may be sufficient to control the symptoms. Potassium iodide, systemic and intralesional corticosteroids, non-steroidal anti-inflammatory drugs, salicylates, tumor necrosis factor-α inhibitors, hydroxychloroquine, colchicine, and dapsone are other treatment options available, but some of these drugs are contraindicated in pregnancy while others are considered safe. Before prescribing one of these treatments to a pregnant patient, the patient's obstetrician should be consulted, and a careful risk-benefit analysis should be performed.",
author = "Acosta, {K. Alexandra} and Haver, {Mary Claire} and Brent Kelly",
year = "2013",
month = "6",
doi = "10.1007/s40257-013-0024-x",
language = "English (US)",
volume = "14",
pages = "215--222",
journal = "American Journal of Clinical Dermatology",
issn = "1175-0561",
publisher = "Adis International Ltd",
number = "3",

}

TY - JOUR

T1 - Etiology and therapeutic management of erythema nodosum during pregnancy

T2 - An update

AU - Acosta, K. Alexandra

AU - Haver, Mary Claire

AU - Kelly, Brent

PY - 2013/6

Y1 - 2013/6

N2 - Erythema nodosum (EN) is the most common form of panniculitis. It is characterized by erythematous, raised, tender nodules that usually occur bilaterally on the extensor surfaces of the lower extremities. EN is associated with many underlying conditions including infection, sarcoidosis, malignancy, and pregnancy. Its underlying etiology, however, is unknown in up to half of cases. Pregnancy is thought to create an optimal background for EN to develop, although the exact mechanisms are unclear. Immune complexes may play a role in the pathogenesis of EN during pregnancy, or EN may be a hypersensitivity reaction to either estrogens or progesterone. EN is a self-limiting process, and non-pharmacologic means such as bed rest and elastic web bandages may be sufficient to control the symptoms. Potassium iodide, systemic and intralesional corticosteroids, non-steroidal anti-inflammatory drugs, salicylates, tumor necrosis factor-α inhibitors, hydroxychloroquine, colchicine, and dapsone are other treatment options available, but some of these drugs are contraindicated in pregnancy while others are considered safe. Before prescribing one of these treatments to a pregnant patient, the patient's obstetrician should be consulted, and a careful risk-benefit analysis should be performed.

AB - Erythema nodosum (EN) is the most common form of panniculitis. It is characterized by erythematous, raised, tender nodules that usually occur bilaterally on the extensor surfaces of the lower extremities. EN is associated with many underlying conditions including infection, sarcoidosis, malignancy, and pregnancy. Its underlying etiology, however, is unknown in up to half of cases. Pregnancy is thought to create an optimal background for EN to develop, although the exact mechanisms are unclear. Immune complexes may play a role in the pathogenesis of EN during pregnancy, or EN may be a hypersensitivity reaction to either estrogens or progesterone. EN is a self-limiting process, and non-pharmacologic means such as bed rest and elastic web bandages may be sufficient to control the symptoms. Potassium iodide, systemic and intralesional corticosteroids, non-steroidal anti-inflammatory drugs, salicylates, tumor necrosis factor-α inhibitors, hydroxychloroquine, colchicine, and dapsone are other treatment options available, but some of these drugs are contraindicated in pregnancy while others are considered safe. Before prescribing one of these treatments to a pregnant patient, the patient's obstetrician should be consulted, and a careful risk-benefit analysis should be performed.

UR - http://www.scopus.com/inward/record.url?scp=84878749391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878749391&partnerID=8YFLogxK

U2 - 10.1007/s40257-013-0024-x

DO - 10.1007/s40257-013-0024-x

M3 - Article

C2 - 23625180

AN - SCOPUS:84878749391

VL - 14

SP - 215

EP - 222

JO - American Journal of Clinical Dermatology

JF - American Journal of Clinical Dermatology

SN - 1175-0561

IS - 3

ER -